Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16097301 | 0.98 | POLB (0.46) | POLBPTGS2KCNH2GPR84LIPG | |
| SCHEMBL8169941 | 0.92 | POLB (0.46) | POLBKCNH2GPR84PARP1 | |
| SCHEMBL11498419 | 0.90 | LIPG (0.40) | PTGS2KCNH2LIPG | |
| SCHEMBL6753968 | 0.84 | POLB (0.47) | POLB | |
| SCHEMBL5280975 | 0.84 | HPGD (0.39) | POLBPTGS2KCNH2GPR84 | |
| SCHEMBL6755300 | 0.83 | POLB (0.46) | POLBKCNH2GPR84 | |
| SCHEMBL15553340 | 0.83 | KCNH2 (0.45) | PTGS2KCNH2GPR84 | |
| SCHEMBL6759148 | 0.83 | POLB (0.46) | POLBKCNH2GPR84 | |
| SCHEMBL6756127 | 0.83 | POLB (0.46) | POLBKCNH2GPR84 | |
| SCHEMBL6759162 | 0.83 | POLB (0.46) | POLBKCNH2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482928-B1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS,COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2009-09-23 | — | — | EP | disclosed |
| US-7345075-B2 | 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester; antiinflammatory agents; microglia activators; neurodegenerative diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-03-18 | — | — | US | disclosed |
| US-7329679-B2 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7115645-B2 | 1,2 diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1077700-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1079830-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | Avanir Pharmaceuticals (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1077700-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE | Avanir Pharmaceuticals (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061019-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999061020-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | POLB 3017/4885PTGS2 24/4885KCNH2 1994/4885 |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | POLB 3017/4885PTGS2 24/4885KCNH2 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.